Is Tirzepatide Bad For You? What the Clinical Evidence Shows

What the trial data found — and what that means for safety

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity over 72 weeks. At the highest dose, participants lost an average of around 20–21% of body weight. That kind of result only reaches regulators when accompanying safety data are also robust, and in SURMOUNT-1, serious adverse events were broadly comparable between the tirzepatide and placebo arms. The most common reason people stopped treatment was gastrointestinal side effects, which affected a meaningful minority but not the majority.

That context matters. Asking whether tirzepatide is bad for you is really asking two separate questions: does it cause harm in the average person who takes it as prescribed, and are there specific circumstances where the risk genuinely outweighs the benefit? The answer to the first is largely no; the answer to the second is yes, for a defined set of situations covered below.

The NHS medicines page for tirzepatide lists the full side-effect profile drawn from the licensed product information. Consulting it directly is the fastest way to check whether a symptom you have noticed is documented.

The side effects that are genuinely common, and how they behave

Nausea is the one people hear about most, and it is real. Vomiting, loose stools, constipation, indigestion, and a general sluggishness in the stomach are all part of tirzepatide's GI profile. These effects tend to be front-loaded: they peak after starting treatment or after a dose increase, then ease over days to a couple of weeks for most people. The titration schedule (beginning at 2.5mg before any increase) exists specifically to let the body adjust gradually.

Injection-site reactions, headache, dizziness and fatigue are also reported. Less commonly, gallbladder problems can occur; people experiencing upper-right abdominal pain should contact their prescriber rather than wait. Dehydration from persistent vomiting or diarrhoea is a practical risk worth knowing about: staying hydrated when GI symptoms are active, and flagging prolonged symptoms to a clinician, is one of the simplest habits to build in. You can check whether your symptoms are listed in the patient information leaflet that comes with your pen in under a minute by searching the medicine name at the eMC.

A question our prescribers hear regularly: does tirzepatide damage the kidneys or liver? Current evidence does not suggest it does in people without pre-existing severe renal or hepatic impairment. The prescriber's assessment is the right place to explore individual risk here.

Where tirzepatide is genuinely not appropriate

The MHRA's January 2026 Drug Safety Update made acute pancreatitis a formal headline for GLP-1 medicines. It is infrequent, but it can be serious. Severe stomach pain that radiates to the back, with or without vomiting, should prompt urgent medical assessment rather than waiting for the next dose or the next appointment. People with a personal history of pancreatitis need a careful prescriber conversation before starting.

Tirzepatide is also not suitable for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It is not licensed for use in pregnancy, breastfeeding, or for anyone trying to conceive. Under-18s are outside the licensed indication entirely. None of these are edge cases to dismiss, they are the situations where the answer to "is tirzepatide bad for you?" is a clear yes, and where a thorough clinical assessment prevents the wrong prescription from being issued.

You can read more about the UK-specific considerations for Mounjaro and personal health circumstances or explore the tirzepatide overview for a fuller picture of how the medicine works.

How a proper prescribing process changes the risk calculation

The risk profile of any prescription medicine changes substantially depending on whether it has been prescribed appropriately. A prescriber who checks for contraindications, reviews other medicines for interactions, confirms the right eligibility criteria, and monitors for early warning signs is doing something an algorithm or an unverified seller cannot replicate. That is why tirzepatide is a Prescription-Only Medicine in the UK, and why access through a GPhC-registered pharmacy matters.

Eli Lilly's UK price increase in autumn 2025 pushed more people to search for cheaper sources, and the MHRA has documented significant enforcement action against counterfeit tirzepatide pens; if you are also wondering whether tirzepatide is the same thing as Mounjaro, that question is worth answering before you buy, you can read more about what that price shift meant on our Eli Lilly Mounjaro price increase page. Counterfeit pens carry risks entirely separate from the medicine itself: unknown contents, no cold-chain guarantees, no clinical oversight, and if you are storing your pen at home it is also worth reading about whether tirzepatide can go bad so you know the signs of a compromised pen. The background on what to look for in a legitimate supply is covered on our Mounjaro information page.

If you have read this far and you are still uncertain whether tirzepatide is bad for your particular situation, that uncertainty is the right prompt to speak to a clinician rather than to search for a more reassuring answer online. Our prescribers cover this kind of question directly, and a consultation with our clinical team is a sensible next step.